What sector does Lincoln Pharma Ltd belong to?

Lincoln Pharma Ltd operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of LINCOLN?

As of the latest available quote, LINCOLN traded at ₹623.50. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of LINCOLN?

Lincoln Pharma Ltd has a price-to-earnings (P/E) ratio of about 12.95. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of LINCOLN?

The market capitalisation of Lincoln Pharma Ltd is approximately ₹1,249 Cr.

Is Lincoln Pharma Ltd profitable?

For its latest reported financial year, Lincoln Pharma Ltd recorded a net profit margin of about 13.11%.

Does LINCOLN pay a dividend?

Lincoln Pharma Ltd does not currently show a dividend yield in our data.

What is the return on equity (ROE) of LINCOLN?

Lincoln Pharma Ltd has a return on equity (ROE) of about 12.30%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of LINCOLN?

Over the past 52 weeks, LINCOLN has traded between a low of ₹440.00 and a high of ₹770.00.

Lincoln Pharma Ltd

LINCOLN NSE Healthcare Pharmaceuticals

₹623.50

-1.72%

Delayed · cached 15 min

Fair value analysis

LINCOLN

Lincoln Pharma Ltd

₹634.40

Close used for this calculation

₹891.23Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

60/100

Profitability15/25

Returns11/25

Balance Sheet21/25

Efficiency13/25

Growth11/25

Good

Quality radar

Consensus fair value

₹891.23

Below FV

▲ +40.5% against the close used

Model range ₹280.83 – ₹1,566.52

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹280.83Fair value₹891.23Bull₹1,566.52

FairClose

52-week traded range

52W low ₹444.2052W high ₹758.15

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Lincoln Pharma Ltd closed at ₹634.40, 28.8% below the consensus fair value of ₹891.23 drawn from 9 valuation models.

Financial DNA score 60/100 — Good. P/E of 13.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹712.04

+12.2%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=6.4%, r=10%, tg=3%, n=10yr

Graham Number

₹644.05

+1.5%

√(22.5 × EPS × BVPS)

EPS=43.88, BVPS=420.13

Graham Formula

₹867.88

+36.8%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=6.4%, FD=7%

P/E Fair Value

₹1,566.52

+146.9%

EPS × 35.7x (sector P/E)

EPS=43.88, Sector P/E=35.7x

Peter Lynch (PEG)

₹280.83

-55.7%

EPS × Growth% (PEG = 1 is fair)

EPS=43.88, g=6.4%

EV/EBITDA

₹748.89

+18.0%

(EBITDA × 13.2x − Net Debt) ÷ Shares

EBITDA=1.12B

Book Value (P/B)

₹661.71

+4.3%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=420.13, ROE=12.3%, g=6%, r=10%

Reverse DCF

₹634.40

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 2.8% | Historical: 6.4%

Margin of Safety

₹710.72

+12.0%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=947.62, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer